UPDATE: Wunderlich Securities Raises PT on Abiomed to $27

Wunderlich Securities reiterates its Buy rating on Abiomed

and raises its price target to $27 from $24 following a quarter in which the company's operating leverage reached impressive levels driven by strong revenue. Wunderlich notes, "We believe investors will begin to recognize the significant operating leverage at Abiomed, as the company begins to transition into a strong earnings growth story. Impella revenues increased a 31% worldwide, well above our 22% estimate, and the operating leverage resulted in GAAP earnings of $0.07 per share, well above our $0.00 estimate." ABMD closed at $20.98 a share on Friday.